The role of inositol in improving fertility in patients with PCOS
DOI:
https://doi.org/10.12775/JEHS.2024.57.009Keywords
polycystic ovary syndrome, inositols, myo-inositol, d-chiro-inositol, assisted reproductive technology, insulin resistanceAbstract
Introduction and purpose
Polycystic ovary syndrome is a common reproductive disorder, accompanied primarily
by hyperandrogenism and insulin resistance. Myo-inositol (MI) and D-chiro-inositol (DCI), have emerged as potential therapeutic agents due to their role as insulin sensitizers. This article examines the effects of inositol therapy on fertility in women with PCOS and its role in assisted reproductive technology (ART). Studies suggest that inositols alleviate irregular menstruation, reduce androgen levels and positively affect ovulation rates. MI supplementation has also shown positive effects during controlled ovarian hyperstimulation and IVF procedures, reducing the required FSH dose and cycle length. However, despite positive results on ovulation and menstrual regularity, the article indicates the need for further studies to establish inositol as standard ART therapy in patients with PCOS.
Material and methods
The following review was based on articles from the PubMed and Google Scholar databases. Key search terms included polycystic ovary syndrome; assisted reproductive treatment, insulin resistance, inositols, Myo-inositol, D-chiro-inositol.
Conclusions
Inositols are a promising therapeutic option for women with PCOS. They have been shown to have positive effects on improving insulin sensitivity and fertility. However, despite inositol's safety and easy availability, the ideal dose and timing of use, the appropriate MI/DCI ratio, as well as the potential side effects of excess DCI and the problem of inositol resistance, require further comprehensive studies.
References
Laganà AS, Rossetti P, Buscema M, La Vignera S, Condorelli RA, Gullo G, et al. Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols. Int J Endocrinol [Internet]. 2016 [cited 2023 Nov 30];2016. Available from: https://pubmed.ncbi.nlm.nih.gov/27579037/
Gupta D, Khan S, Islam M, Malik BH, Rutkofsky I. Myo-Inositol’s Role in Assisted Reproductive Technology: Evidence for Improving the Quality of Oocytes and Embryos in Patients With Polycystic Ovary Syndrome. Cureus [Internet]. 2020 May 13 [cited 2023 Nov 30];12(5). Available from: https://pubmed.ncbi.nlm.nih.gov/32542134/
Fauser BCJM, Tarlatzis, Fauser, Chang, Aziz, Legro, et al. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod [Internet]. 2004 Jan [cited 2023 Nov 30];19(1):41–7. Available from: https://pubmed.ncbi.nlm.nih.gov/14688154/
Tanbo T, Mellembakken J, Bjercke S, Ring E, Åbyholm T, Fedorcsak P. Ovulation induction in polycystic ovary syndrome. Acta Obstet Gynecol Scand [Internet]. 2018 Oct 1 [cited 2023 Nov 30];97(10):1162–7. Available from: https://pubmed.ncbi.nlm.nih.gov/29889977/
Kamenov Z, Gateva A. Inositols in PCOS. Molecules [Internet]. 2020 Dec 1 [cited 2023 Nov 30];25(23). Available from: https://pubmed.ncbi.nlm.nih.gov/33260918/
Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med [Internet]. 2010 Jun 30 [cited 2023 Dec 1];8. Available from: https://pubmed.ncbi.nlm.nih.gov/20591140/
Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update [Internet]. 2016 Nov 1 [cited 2023 Dec 1];22(6):687–708. Available from: https://pubmed.ncbi.nlm.nih.gov/27511809/
Macut D, Bjekić-Macut J, Rahelić D, Doknić M. Insulin and the polycystic ovary syndrome. Diabetes Res Clin Pract. 2017 Aug 1;130:163–70.
Laganà AS, Garzon S, Casarin J, Franchi M, Ghezzi F. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach. Trends Endocrinol Metab [Internet]. 2018 Nov 1 [cited 2023 Nov 30];29(11):768–80. Available from: https://pubmed.ncbi.nlm.nih.gov/30270194/
Chiu TTY, Rogers MS, Law ELK, Briton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Human Reproduction [Internet]. 2002 Jun 1 [cited 2023 Dec 1];17(6):1591–6. Available from: https://dx.doi.org/10.1093/humrep/17.6.1591
Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev [Internet]. 2019 Mar 28 [cited 2023 Dec 2];3(3). Available from: https://pubmed.ncbi.nlm.nih.gov/30921477/
Mendoza N, Losa F, Palacios S. Strategy to improve the female fertility in the general gynecologist’s office: use of a nutritional supplement based on myo-inositol/D-chiro-inositol and antioxidants. Gynecol Endocrinol [Internet]. 2022 [cited 2023 Nov 30];38(4):275–8. Available from: https://pubmed.ncbi.nlm.nih.gov/34931570/
Sortino MA, Salomone S, Carruba MO, Drago F. Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols. Front Pharmacol [Internet]. 2017 Jun 8 [cited 2023 Nov 30];8(JUN). Available from: https://pubmed.ncbi.nlm.nih.gov/28642705/
Merviel P, James P, Bouée S, Le Guillou M, Rince C, Nachtergaele C, et al. Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. Reprod Health [Internet]. 2021 Dec 1 [cited 2023 Nov 30];18(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33468143/
Lazarenko R, Geisler J, Bayliss D, Larner J, Li C. D-chiro-inositol glycan stimulates insulin secretion in pancreatic β cells. Mol Cell Endocrinol [Internet]. 2014 Apr 25 [cited 2023 Dec 4];387(1–2):1–7. Available from: https://pubmed.ncbi.nlm.nih.gov/24530497/
Facchinetti F, Unfer V, Dewailly D, Kamenov ZA, Diamanti-Kandarakis E, Laganà AS, et al. Inositols in Polycystic Ovary Syndrome: An Overview on the Advances. Trends Endocrinol Metab [Internet]. 2020 Jun 1 [cited 2023 Nov 30];31(6):435–47. Available from: https://pubmed.ncbi.nlm.nih.gov/32396844/
Zacchè MM, Caputo L, Filippis S, Zacchè G, Dindelli M, Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol [Internet]. 2009 [cited 2023 Dec 5];25(8):508–13. Available from: https://pubmed.ncbi.nlm.nih.gov/19551544/
De Diego MV, Gómez-Pardo O, Groar JK, López-Escobar A, Martín-Estal I, Castilla-Cortázar I, et al. Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study. Arch Gynecol Obstet [Internet]. 2020 Nov 1 [cited 2023 Dec 5];302(5):1169–79. Available from: https://pubmed.ncbi.nlm.nih.gov/32770354/
Pundir J, Psaroudakis D, Savnur P, Bhide P, Sabatini L, Teede H, et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG [Internet]. 2018 Feb 1 [cited 2023 Dec 7];125(3):299–308. Available from: https://pubmed.ncbi.nlm.nih.gov/28544572/
Gambioli R, Forte G, Buzzaccarini G, Unfer V, Laganà AS. Myo-Inositol as a Key Supporter of Fertility and Physiological Gestation. Pharmaceuticals (Basel) [Internet]. 2021 [cited 2023 Nov 30];14(6). Available from: https://pubmed.ncbi.nlm.nih.gov/34070701/
Facchinetti F, Appetecchia M, Aragona C, Bevilacqua A, Bezerra Espinola MS, Bizzarri M, et al. Experts’ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. Expert Opin Drug Metab Toxicol [Internet]. 2020 Mar 3 [cited 2023 Nov 30];16(3):255–74. Available from: https://pubmed.ncbi.nlm.nih.gov/32129111/
Dinicola S, Unfer V, Facchinetti F, Soulage CO, Greene ND, Bizzarri M, et al. Inositols: From Established Knowledge to Novel Approaches. Int J Mol Sci [Internet]. 2021 Oct 1 [cited 2023 Nov 30];22(19). Available from: https://pubmed.ncbi.nlm.nih.gov/34638926/
Facchinetti F, Espinola MSB, Dewailly D, Ozay AC, Prapas N, Vazquez-Levin M, et al. Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART). Trends Endocrinol Metab [Internet]. 2020 Aug 1 [cited 2023 Nov 30];31(8):570–9. Available from: https://pubmed.ncbi.nlm.nih.gov/32418772/
Wdowiak A. Myoinositol Improves Embryo Development in PCOS Patients Undergoing ICSI. Int J Endocrinol. 2016 Jan 1;2016:6273298.
Bhide P, Pundir J, Gudi A, Shah A, Homburg R, Acharya G. The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: A systematic review and meta-analysis. Acta Obstet Gynecol Scand [Internet]. 2019 Oct 1 [cited 2023 Nov 30];98(10):1235–44. Available from: https://pubmed.ncbi.nlm.nih.gov/30993683/
Etrusco A, Laganà AS, Chiantera V, Buzzaccarini G, Unfer V. Myo-inositol in assisted reproductive technology from bench to bedside. Trends Endocrinol Metab [Internet]. 2023 [cited 2023 Nov 30]; Available from: https://pubmed.ncbi.nlm.nih.gov/37798243/
Monastra G, Sambuy Y, Ferruzza S, Ferrari D, Ranaldi G. Alpha-lactalbumin Effect on Myo-inositol Intestinal Absorption: In vivo and In vitro. Curr Drug Deliv [Internet]. 2018 May 10 [cited 2024 Jan 15];15(9):1305–11. Available from: https://pubmed.ncbi.nlm.nih.gov/29745333/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Kamila Turek, Anna Greguła, Karol Stachyrak, Dawid Mika, Aleksandra Kłos, Bartosz Mazur, Maciej Lambach, Mateusz Pawlicki, Aleksandra Mazurek, Wiktoria Wilanowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 602
Number of citations: 0
